Inhibikase Therapeutics (IKT) Debt to Equity (2020 - 2025)
Inhibikase Therapeutics (IKT) has 6 years of Debt to Equity data on record, last reported at $0.0 in Q2 2025.
- On a quarterly basis, Debt to Equity fell 98.41% to $0.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $0.0, a 98.41% decrease, with the full-year FY2024 number at $0.0, down 91.48% from a year prior.
- Debt to Equity reached $0.0 in Q2 2025 per IKT's latest filing, down from $0.0 in the prior quarter.
- Over the last five years, Debt to Equity for IKT hit a ceiling of $0.03 in Q1 2021 and a floor of -$0.27 in Q3 2024.
- A 5-year average of -$0.01 and a median of $0.01 in 2023 define the central range for Debt to Equity.
- On a YoY basis, Debt to Equity climbed as much as 292.9% in 2024 and fell as far as 2857.86% in 2024.
- Tracing IKT's Debt to Equity over 5 years: stood at $0.01 in 2021, then surged by 31.06% to $0.01 in 2022, then surged by 97.21% to $0.01 in 2023, then tumbled by 91.48% to $0.0 in 2024, then crashed by 59.31% to $0.0 in 2025.
- Business Quant data shows Debt to Equity for IKT at $0.0 in Q2 2025, $0.0 in Q1 2025, and $0.0 in Q4 2024.